Black Diamond Therapeutics
BDTX
90 hedge funds and large institutions have $218M invested in Black Diamond Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 27 closing their positions.
185% more call options, than puts
Call options by funds: $331K | Put options by funds: $116K
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
9% more capital invested
Capital invested by funds: $200M → $218M (+$18M)
6.89% more ownership
Funds ownership: 76.24% → 83.13% (+6.9%)
2% more funds holding
Funds holding: 88 → 90 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$21.1M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$11.3M |
| 3 |
BlackRock
New York
|
+$9.86M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$4.48M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.9M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$4.45M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.52M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.14M |
| 5 |
Goldman Sachs
New York
|
-$1.45M |
BDTX Hedge Fund Activity: Q2 2024 in Review
90 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2024, worth a combined $218M — up 9% from $200M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BDTX positions and 27 closed out — a net gain of 4 holders — while 25 added to existing stakes and 19 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $21.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.9M sold.
- 90 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2024, up from 88 in Q1 2024.
- Funds reported $218M of Black Diamond Therapeutics stock for Q2 2024, up 9% quarter-over-quarter.
- 31 funds opened new Black Diamond Therapeutics positions in Q2 2024 and 27 closed out, a net change of +4 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2024 was T. Rowe Price Investment Management, an estimated $21.1M added.
- The largest Black Diamond Therapeutics seller in Q2 2024 was RA Capital Management, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2024.